Financial Performance - Reported net sales for the full year 2024 were $11.48 billion, flat compared to the prior year, with currency neutral sales increasing by 6%[5] - Adjusted operating EBITDA for the full year was $2.21 billion, reflecting a 16% increase on a comparable basis due to strong volume growth and productivity gains[5] - Reported earnings per share (EPS) for the full year was $0.95, while adjusted EPS excluding amortization was $4.31 per diluted share[5] - For the fourth quarter, reported net sales were $2.77 billion, a 3% increase year-over-year, with currency neutral sales up 6%[8] - Adjusted operating EBITDA for the fourth quarter was $471 million, with a comparable increase of 5% driven by volume growth and productivity gains[10] - Net income for the year ended December 31, 2024, was $247 million, a significant improvement from a net loss of $2,563 million in 2023[42] - Reported (GAAP) Net Income for 2024 was $278 million, a recovery from a net loss of $2,518 million in 2023[68] - Adjusted (Non-GAAP) Net Income for the year ended December 31, 2024, was $646 million, up from $328 million in 2023, representing a growth of 96.34%[70] Segment Performance - The Nourish segment reported a 4% increase in comparable currency neutral sales, while Health & Biosciences and Scent segments saw increases of 6% and 7% respectively[9] - The Nourish segment reported net sales of $5,871 million in 2024, down from $6,060 million in 2023, a decrease of about 3.1%[45] - Health & Biosciences segment sales increased by 6.3% to $2,212 million in 2024, compared to $2,081 million in 2023[84] - Scent segment sales grew to $2,440 million in 2024, up 7.1% from $2,277 million in 2023[84] - Pharma Solutions segment sales reached $961 million in 2024, a slight increase from $945 million in 2023[84] - The company experienced a 12% increase in Pharma Solutions sales, with a remarkable 81% increase in segment adjusted operating EBITDA for Q4 2024[89] Future Projections - Full year 2025 sales are expected to be in the range of $10.6 billion to $10.9 billion, with adjusted operating EBITDA projected between $2 billion and $2.15 billion[12] - The company anticipates comparable currency neutral sales growth of 1% to 4% in 2025, with adjusted operating EBITDA expected to grow 5% to 10% year-over-year[13] - Foreign exchange is expected to have a 4% adverse impact on sales growth and a 6% adverse impact on adjusted operating EBITDA growth in 2025[14] - The Pharma Solutions segment is expected to contribute six months of results in 2025 following its divestiture, which is assumed to close on June 30, 2025[12] Expenses and Cash Flow - Research and development expenses increased by 8% to $170 million in Q4 2024 from $157 million in Q4 2023[38] - Selling and administrative expenses rose by 16% to $517 million in Q4 2024, up from $444 million in Q4 2023[38] - Total net cash provided by operating activities decreased to $1,070 million in 2024 from $1,439 million in 2023, reflecting a decline of approximately 25.6%[42] - The company incurred approximately $1,995 million in Selling and Administrative Expenses for 2024, compared to $1,787 million in 2023, reflecting an increase of 11.65%[65] - Net cash used in financing activities was $1,606 million in 2024, a decrease from $1,851 million in 2023, reflecting a reduction of approximately 13.2%[42] Balance Sheet - Total current assets increased to $7,993 million in 2024 from $6,293 million in 2023[40] - Total liabilities decreased to $14,256 million in 2024 from $15,578 million in 2023[40] - The company’s total assets were $28,667 million in 2024, down from $30,978 million in 2023[40] - Total debt as of December 31, 2024, was $9,005 million, resulting in net debt of $8,534 million after accounting for $471 million in cash and cash equivalents[80] Other Notable Items - The company reported a net loss of $46 million in Q4 2024, a significant improvement from a net loss of $2,609 million in Q4 2023[38] - The company recognized a settlement loss of $130 million related to the termination of the pension plan in 2024[74] - The company incurred an impairment of goodwill of $64 million in 2024, a significant reduction from $2,623 million in 2023[45] - Business divestiture costs for Q4 2024 were approximately $56 million, compared to $38 million in Q4 2023, marking an increase of 47.37%[60] - For the year ended December 31, 2024, business divestiture and integration costs were approximately $220 million and $5 million, respectively, compared to $108 million and $59 million in 2023[73]

Wall Street analysts expect International Flavors (IFF) to post quarterly earnings of $0.78 per share in its upcoming report, which indicates a year-over-year increase of 8.3%. Revenues are expected to be $2.67 billion, down 1.4% from the year-ago quarter.The consensus EPS estimate for the quarter has been revised 2.5% lower over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initial estimates during this timeframe.Before a compan ...

International Flavors & Fragrances Inc. (IFF) is scheduled to report fourth-quarter 2024 results on Feb. 18, after the closing bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The Zacks Consensus Estimate for IFF’s revenues is pegged at $2.67 billion, indicating a 1.37% dip from the year-ago reported figure.The consensus estimate for earnings is pegged at 78 cents per share. The consensus estimate for IFF’s earnings has moved down 2.5% in the past 60 days. The estimate indicates ...

International Flavors & Fragrances Inc. (IFF) is poised to gain from the end-market demand for flavors and fragrances. IFF’s initiatives are also expected to aid its performance. Improved volumes across all its segments in recent quarters will also drive the company’s performance.Let us delve deeper and analyze the factors that make International Flavors stock worth holding on to at present.Demand for Flavors & Fragrances Drives IFF’s GrowthInternational Flavors is well-poised to benefit from the demand for ...

Have you looked into how International Flavors (IFF) performed internationally during the quarter ending September 2024? Considering the widespread global presence of this ingredients producer for food, cosmetics and consumer products industries, examining the trends in international revenues is essential for assessing its financial resilience and prospects for growth.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its ...

International Flavors (IFF) has been beaten down lately with too much selling pressure. While the stock has lost 14.2% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Here is How to Spot Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillat ...

International Flavors & Fragrances Inc. (IFF) reported adjusted earnings of $1.04 per share in third-quarter 2024, missing the Zacks Consensus Estimate of $1.06 per share. However, the bottom line improved 17% from the year-ago quarter.Including one-time items, the company reported earnings of 23 cents per share compared with the prior-year quarter’s 10 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.International Flavors’ net sales rose 3.7% year over year to $2.93 bi ...

Core Insights - International Flavors (IFF) reported revenue of $2.93 billion for the quarter ended September 2024, reflecting a year-over-year increase of 3.7% [1] - Earnings per share (EPS) for the quarter was $1.04, up from $0.89 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $2.83 billion by 3.25%, while the EPS fell short of the consensus estimate of $1.06 by 1.89% [1] Revenue Performance by Segment - Net Sales in the Nourish segment reached $1.49 billion, surpassing the average estimate of $1.44 billion, marking a 2.6% increase year-over-year [3] - Net Sales in the Scent segment were $613 million, slightly below the estimated $629.75 million, representing a minor decline of 0.3% compared to the previous year [3] - Net Sales in Pharma Solutions amounted to $256 million, exceeding the average estimate of $240.35 million, with a year-over-year growth of 7.6% [3] - Net Sales in Health & Biosciences reached $570 million, surpassing the estimated $531.83 million, reflecting a significant increase of 10% year-over-year [3] Adjusted Operating EBITDA Performance - Adjusted Operating EBITDA for the Nourish segment was $206 million, slightly below the estimate of $207.69 million [3] - Adjusted Operating EBITDA for Pharma Solutions was $62 million, exceeding the average estimate of $47.74 million [3] - Adjusted Operating EBITDA for the Scent segment was $127 million, falling short of the estimated $137.51 million [3] - Adjusted Operating EBITDA for Health & Biosciences was $173 million, surpassing the average estimate of $155.24 million [3] Stock Performance - Shares of International Flavors have returned -1.8% over the past month, compared to a -0.5% change in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating potential for outperformance in the near term [4]

Core Viewpoint - International Flavors (IFF) reported quarterly earnings of $1.04 per share, missing the Zacks Consensus Estimate of $1.06 per share, but showing an increase from $0.89 per share a year ago [1][2] Financial Performance - The company posted revenues of $2.93 billion for the quarter ended September 2024, surpassing the Zacks Consensus Estimate by 3.25% and up from $2.82 billion year-over-year [3] - The earnings surprise for the quarter was -1.89%, while the previous quarter saw a positive surprise of 14.85% [2] Stock Performance - IFF shares have increased approximately 22.2% since the beginning of the year, outperforming the S&P 500's gain of 19.8% [4] - The stock currently holds a Zacks Rank 1 (Strong Buy), indicating expectations for outperformance in the near future [7] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.81 on revenues of $2.67 billion, and for the current fiscal year, it is $4.24 on revenues of $11.3 billion [8] - The estimate revisions trend for IFF is favorable, which could influence future stock movements [6][7] Industry Context - The Chemical - Specialty industry, to which IFF belongs, is currently ranked in the bottom 46% of over 250 Zacks industries, which may impact stock performance [9]

Financial Performance - Q3 2024 reported net sales were $2.93 billion, a 4% increase YoY, with currency-neutral sales up 9% YoY[3] - Q3 2024 adjusted operating EBITDA was $568 million, a 16% increase YoY on a comparable basis[3] - Q3 2024 adjusted EPS excluding amortization was $1.04, a 17% increase YoY[3] - Q3 2024 cash flows from operations were $702 million, with free cash flow of $399 million[4] - Net sales for Q3 2024 increased by 4% to $2.925 billion compared to $2.820 billion in Q3 2023[31] - Gross profit for Q3 2024 rose by 14% to $1.052 billion from $924 million in Q3 2023[31] - Operating profit for Q3 2024 surged by 66% to $249 million from $150 million in Q3 2023[31] - Net income attributable to IFF shareholders for Q3 2024 jumped by 136% to $59 million from $25 million in Q3 2023[31] - Free cash flow for the nine months ended September 30, 2024, was $702 million, compared to $795 million in the same period in 2023[35] - Net sales for the third quarter of 2024 were $2.925 billion, compared to $2.820 billion in the same period of 2023, reflecting a 3.7% increase[37] - Consolidated adjusted operating EBITDA margin improved to 19.4% in Q3 2024, up from 17.9% in Q3 2023[37] - Adjusted (Non-GAAP) net income for Q3 2024 was $158 million, compared to $96 million in Q3 2023, a 64.6% increase[43] - Adjusted (Non-GAAP) EPS for Q3 2024 was $0.62, up from $0.38 in Q3 2023[43] - Reported (GAAP) gross profit for Q3 2024 was $1.052 billion, unchanged from the adjusted (Non-GAAP) figure[39] - Year-to-date reported (GAAP) gross profit for 2024 was $3.144 billion, compared to $2.821 billion in 2023[50] - Adjusted (Non-GAAP) net income excluding amortization for Q3 2024 was $268 million, compared to $227 million in Q3 2023[44] - Net income attributable to IFF for Q3 2024 was $289 million, with a diluted EPS of $1.13[54] - Adjusted (Non-GAAP) net income for Q3 2024 was $503 million, with a diluted EPS of $1.96[54] - Adjusted (Non-GAAP) net income excluding amortization for Q3 2024 was $855 million, with a diluted EPS of $3.34[55] - Total net sales for Q3 2024 were $2.925 billion, compared to $2.785 billion in Q3 2023[65] - Segment adjusted operating EBITDA for Q3 2024 was $568 million, up from $490 million in Q3 2023[65] - Q3 Consolidated sales grew by 4% reported, with a 12% increase in Adjusted Operating EBITDA and a 1.5% margin improvement[71] - YTD Consolidated sales decreased by 1% reported, but Adjusted Operating EBITDA increased by 14% with a 2.6% margin improvement[76] Segment Performance - Nourish segment reported Q3 sales of $1.49 billion, with currency-neutral sales up 7% YoY[6] - Health & Biosciences segment reported Q3 sales of $570 million, with currency-neutral sales up 12% YoY[7] - Scent segment reported Q3 sales of $613 million, with currency-neutral sales up 10% YoY[8] - Pharma Solutions segment reported Q3 sales of $256 million, with currency-neutral sales up 8% YoY[8] - Nourish segment sales increased to $1.486 billion in Q3 2024, up 2.6% from $1.449 billion in Q3 2023[37] - Health & Biosciences segment sales grew by 10.0% to $570 million in Q3 2024, compared to $518 million in Q3 2023[37] - Nourish segment sales for Q3 2024 were $1.486 billion, with a segment adjusted operating EBITDA margin of 13.9%[65] - Scent segment sales for Q3 2024 were $613 million, with a segment adjusted operating EBITDA margin of 20.7%[65] - Pharma Solutions segment sales for Q3 2024 were $256 million, with a segment adjusted operating EBITDA margin of 24.2%[65] - Q3 Nourish segment sales increased by 3% reported, with a 16% increase in Segment Adjusted Operating EBITDA and a 1.6% margin improvement[67] - Q3 Scent segment sales remained flat (0% reported), but Segment Adjusted Operating EBITDA decreased by 3% with a 0.6% margin decline[68] - Q3 Pharma Solutions segment sales grew by 8% reported, with a significant 32% increase in Segment Adjusted Operating EBITDA and a 4.5% margin improvement[69] - Q3 Health & Biosciences segment sales increased by 10% reported, with a 15% rise in Segment Adjusted Operating EBITDA and a 1.4% margin improvement[70] - YTD Nourish segment sales decreased by 4% reported, but Segment Adjusted Operating EBITDA increased by 15% with a 2.5% margin improvement[72] - YTD Scent segment sales grew by 3% reported, with a 19% increase in Segment Adjusted Operating EBITDA and a 3.2% margin improvement[73] - YTD Pharma Solutions segment sales decreased by 1% reported, with a 6% decline in Segment Adjusted Operating EBITDA and a 1.2% margin decrease[74] - YTD Health & Biosciences segment sales increased by 7% reported, with a 17% rise in Segment Adjusted Operating EBITDA and a 2.6% margin improvement[75] Financial Guidance - Full-year 2024 sales guidance increased to $11.3-$11.4 billion, with adjusted operating EBITDA expected at the high end of $2.1-$2.17 billion[9] - Volume growth for 2024 is expected to be 5-6%, up from the previous guidance of 3-5%[9] Debt and Leverage - Net debt to credit adjusted EBITDA is used as a leverage ratio in the company's credit agreements[26] - Total debt as of September 30, 2024, was $9.127 billion, with net debt of $8.558 billion after adjusting for cash and cash equivalents[62] - Credit adjusted EBITDA for the twelve months ended September 30, 2024, was $2.201 billion[61] Non-GAAP Adjustments - Adjusted operating EBITDA excludes depreciation, amortization, interest expense, and certain non-recurring items[24] - Currency neutral metrics are used to eliminate the effects of translating non-U.S. currencies to U.S. dollars[23] - Business divestiture costs for Q3 2024 were approximately $55 million, compared to $29 million in Q3 2023[47] Assets and Cash Position - The company's total assets as of September 30, 2024, were $29.928 billion, down from $30.978 billion at the end of 2023[33] - Cash, cash equivalents, and restricted cash at the end of Q3 2024 were $569 million, down from $662 million at the end of Q3 2023[35]